Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.

about

Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.

Item

http://www.wikidata.org/entity/Q47944297

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Optimizing Somatostatin Analog ...... creatic Neuroendocrine Tumors.

@en

Optimizing Somatostatin Analog ...... creatic Neuroendocrine Tumors.

@nl

type

Item

label

Optimizing Somatostatin Analog ...... creatic Neuroendocrine Tumors.

@en

Optimizing Somatostatin Analog ...... creatic Neuroendocrine Tumors.

@nl

prefLabel

Optimizing Somatostatin Analog ...... creatic Neuroendocrine Tumors.

@en

Optimizing Somatostatin Analog ...... creatic Neuroendocrine Tumors.

@nl

P1476

Optimizing Somatostatin Analog ...... ncreatic Neuroendocrine Tumors

@en

P2093

Alberto Carmona-Bayonas

http://www.w3.org/2001/XMLSchema#string

Ana Custodio

http://www.w3.org/2001/XMLSchema#string

Carlos López

http://www.w3.org/2001/XMLSchema#string

Enrique Grande

http://www.w3.org/2001/XMLSchema#string

Jaume Capdevila

http://www.w3.org/2001/XMLSchema#string

Paula Jiménez-Fonseca

http://www.w3.org/2001/XMLSchema#string

Spanish Neuroendocrine Tumor Group (GETNE)

http://www.w3.org/2001/XMLSchema#string

P2860

Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly

Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study.

Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network.

Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.

Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Everolimus for advanced pancreatic neuroendocrine tumors.

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.

Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients

Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide

P2888

s11912-017-0633-2

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1007/S11912-017-0633-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rocío García-Carbonero

Alex Teulé

P577

2017-09-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28920153

http://www.w3.org/2001/XMLSchema#string